Ischemia and reperfusion injury in uterus transplantation: A comprehensive review.

Viktorija Zitkute, Mindaugas Kvietkauskas, Bettina Leber, Kestutis Strupas, Philipp Stiegler, Peter Schemmer

Journal: Transplantation reviews (Orlando, Fla.) 2021;34(3):100550

PMID: 32498979

Abstract

Uterus transplantation (UTx) is the only available treatment for human beings who cannot carry children out to term. However, despite several clinical studies with a very limited number of UTx many issues have to be addressed. Up to date, there is a limited number of successful UTx with livebirth and the majority was achieved with live donors. Wide clinical application is inherently limited by the lack of organs, ischemia/reperfusion injury (IRI) as well as immunosuppression after UTx. The objective of this comprehensive literature review is to discuss these arising limitations of UTx with main focus on strategies to reduce IRI. This review showed, that usage of immunosuppressants, opioids or supplements, like amino acids, protects uterus from IRI, improving rising level of antioxidants and decreasing level of oxidative stress markers. The available data of experimental and clinical studies was compiled and will be discussed.

Copyright © 2020 Elsevier Inc. All rights reserved.

Address: General, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, Graz, Austria; Faculty of Medicine, Vilnius University, Vilnius, Lithuania.; General, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.; Faculty of Medicine, Vilnius University, Vilnius, Lithuania.; General, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, Graz, Austria. Electronic address: [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.